EPO and chronic kidney disease: Despite the reduction of blood transfusion by increasing the patient's hemoglobin level, the patient is vulnerable to autoinflammation and iron deficiency, which abates the effectiveness of recombinant human erythropoietin in the therapy of patients with CKD and anemia [5].